title: Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles.
abstract: Nanoparticles of a highly soluble macromolecular drug, heparin, were formulated with two biodegradable polymers (poly-E-caprolactone [PCL] and poly (D, L-lactic-co-glycolic-acid) 50/50 [PLAGA]) and two nonbiodegradable positively charged polymers (Eudragit RS and RL) by the double emulsion and solvent evaporation method, using a high-pressure homogenization device. The encapsulation efficiency and heparin release profiles were studied as a function of the type of polymers employed (alone or in combination) and the concentration of heparin. Optimal encapsulation efficiency was observed when 5000 IU of heparin were incorporated in the first emulsion. High drug entrapment efficiency was observed in both Eudragit RS and RL nanoparticles (60% and 98%, respectively), compared with PLAGA and PCL nanoparticles (<14%). The use of the two types of Eudragit in combination with PCL and PLAGA increased the encapsulation efficiency compared with these two biodegradable polymers used alone; however, the in vitro drug release was not modified and remained low. On the other hand, the addition of esterase to the dissolution medium resulted in a significant increase in heparin release. The in vitro biological activity of released heparin, evaluated by measuring the anti-Xa activity by a colorimetric assay, was conserved after the encapsulation process.
authors.affiliation: Laboratoire de Pharmacie Galénique et Biopharmacie, Faculté de Pharmacie, Nancy, France.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Jiao
authors.forename: N
authors.initials: N
authors.lastname: Ubrich
authors.forename: M
authors.initials: M
authors.lastname: Marchand-Arvier
authors.forename: C
authors.initials: C
authors.lastname: Vigneron
authors.forename: M
authors.initials: M
authors.lastname: Hoffman
authors.forename: P
authors.initials: P
authors.lastname: Maincent
mesh_terms: D001673:Biodegradation, Environmental; D001704:Biopolymers; D002214:Capsules; D003692:Delayed-Action Preparations; D004655:Emulsions; D006016:Glycolates / Q000737:chemistry / Q000493:pharmacokinetics*; D006493:Heparin / Q000737:chemistry / Q000493:pharmacokinetics*; D007700:Kinetics; D019344:Lactic Acid; D011091:Polyesters / Q000737:chemistry / Q000493:pharmacokinetics*; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013499:Surface Properties; D013997:Time Factors
chemical_list: D001704:Biopolymers; D002214:Capsules; D003692:Delayed-Action Preparations; D004655:Emulsions; D006016:Glycolates; D011091:Polyesters; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C016240:polycaprolactone; D011100:Polyglycolic Acid; D019344:Lactic Acid; D006493:Heparin